April, 2024
April 2024
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
2930  
Fadi Haddad: P1/2 study of pivekimab
Mar 10, 2024, 12:31

Fadi Haddad: P1/2 study of pivekimab

Fadi Haddad, Assistant Professor, Leukemia Department MD Anderson Cancer Center, Houston, shared a post on X/Twitter:

Out in The Lancet Oncology.

P1/2 study of pivekimab.

CD123-ADC

N=91 with R/R AML

RP2D=0.045 mg/kg q3w

TRAEs=FN, infusion reaction, anemia

ORR=21%; CRc=17%

Next step=AZA/VEN/pivekimab.”

Source: Fadi Haddad/X